|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating expenses: | |||||
| Research and development (including $27 and $32,128 for a related party) | |||||
| General and administrative (including $322 and $230 for a related party) | |||||
| Restructuring costs | |||||
| Impairment costs | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expense), net: | |||||
| Interest income | |||||
| Change in fair value of tranche liability (including $331 and $19,064 for a related party) | |||||
| Change in fair value of derivative liabilities (including $1,165 and $2,039 for a related party) | |||||
| Interest expense (including $1,384 and $2,656 for a related party) | |||||
| Loss on extinguishment and on issuance of convertible promissory notes (including $169 and $34,692 for a related party) | |||||
| Other income, net | |||||
| Loss before income taxes | |||||
| Income tax benefit | |||||
| Total other income (expense), net | |||||
| Net loss | |||||
| Other comprehensive income: | |||||
| Unrealized gain on marketable securities, net of tax | |||||
| Total other comprehensive income | |||||
| Comprehensive loss | |||||
| Net loss per share attributable to common stockholders - basic | |||||
| Net loss per share attributable to common stockholders - diluted | |||||
| Weighted-average shares outstanding - basic | |||||
| Weighted-average shares outstanding - diluted | |||||
Loading...